Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial

SIMPLE SUMMARY: Myeloma, a blood cancer, is rare and hard to diagnose. People often suffer irreversible organ damage by the time of diagnosis. Myeloma is preceded by a premalignant phase that is easily identifiable on a blood test. Currently, there is no screening for this, because most people do no...

Descripción completa

Detalles Bibliográficos
Autores principales: Bowcock, Stella, Atkin, Catherine, Iqbal, Gulnaz, Pratt, Guy, Yong, Kwee, Neal, Richard D., Planche, Tim, Karunanithi, Kamaraj, Jenkins, Stephen, Stern, Simon, Arnott, Sarah, Toth, Peter, Wandroo, Farooq, Dunn, Janet, Drayson, Mark T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341254/
https://www.ncbi.nlm.nih.gov/pubmed/37444449
http://dx.doi.org/10.3390/cancers15133337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341254/
https://www.ncbi.nlm.nih.gov/pubmed/37444449
http://dx.doi.org/10.3390/cancers15133337

Ejemplares similares